Vafseo

Drug AKEBIA THERAPEUTICS INC
Total Payments
$1.4M
Transactions
2,438
Doctors
1,581
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $1.4M 2,438 1,581

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.2M 1 83.0%
Consulting Fee $163,029 45 11.5%
Education $30,976 1,306 2.2%
Food and Beverage $30,762 1,030 2.2%
Travel and Lodging $17,243 56 1.2%

Payments by Type

Research
$1.2M
1 transactions
General
$242,010
2,437 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience AKEBIA THERAPEUTICS INC $1.2M 0

Top Doctors Receiving Payments for Vafseo — Page 3

Doctor Specialty Location Total Records
, MD Nephrology Mcallen, TX $149.40 7
, MD Internal Medicine Spartanburg, SC $144.93 6
, MD Nephrology Houston, TX $143.23 4
, CRNP Gerontology Philadelphia, PA $140.00 1
, CRNP Adult Health Philadelphia, PA $140.00 1
, MD Nephrology Miami, FL $139.54 8
, M.D., M.P.H Nephrology Los Angeles, CA $138.53 7
, ARNP Acute Care Lexington, KY $135.52 1
, M.D Pulmonary Disease Lexington, KY $135.52 1
, MD Nephrology Capitol Heights, MD $134.59 8
, MD Nephrology Kissimmee, FL $129.13 5
, M.D Nephrology Cincinnati, OH $127.75 2
, M.D Nephrology State College, PA $127.74 2
, MD Nephrology Orlando, FL $127.31 5
, M.D., M.P.H Nephrology Tucson, AZ $126.67 1
, M.D Internal Medicine Tucson, AZ $126.67 1
, M.D Internal Medicine Tucson, AZ $126.67 1
, MD Surgery Honolulu, HI $126.67 1
, MD Internal Medicine Tucson, AZ $126.66 1
, MD Nephrology Tucson, AZ $126.66 1
, MD Nephrology Tucson, AZ $126.66 1
, M.D., M.P.H Nephrology Sylacauga, AL $124.99 1
, CRNP Pediatrics Birmingham, AL $124.98 1
, M.D Nephrology San Bernardino, CA $124.77 6
, APRN Adult Health Greenville, SC $123.47 6

About Vafseo

Vafseo is a drug associated with $1.4M in payments to 1,581 healthcare providers, recorded across 2,438 transactions in the CMS Open Payments database. The primary manufacturer is AKEBIA THERAPEUTICS INC.

Payment data is available from 2024 to 2024. In 2024, $1.4M was paid across 2,438 transactions to 1,581 doctors.

The most common payment nature for Vafseo is "Unspecified" ($1.2M, 83.0% of total).

Vafseo is associated with 1 research study, including "Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience" ($1.2M).